# The cumulative dose that decides whether it comes back

Source: https://onco.cc/technologies/rejuv-recovery-cumulative-dose/  
OnCo record `rejuv-recovery-cumulative-dose` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

For several treatments there is a published number above which lasting damage becomes much likelier: the total anthracycline dose and heart failure, the total cisplatin dose and hearing, the radiation dose to the parotid gland and dry mouth. Twenty-three thresholds are listed with their sources, because the total you have had is a question your team can answer.

## Summary

Most late effects are dose-dependent, and for a minority of them somebody has published the dose. Those numbers belong in a patient's hands, because the total received is recorded in the notes and is the one piece of personal information that changes how much any of this applies.

The heart: the doxorubicin label estimates the probability of cardiomyopathy at 1 to 2 per cent at a cumulative 300 mg/m2, 3 to 5 per cent at 400, 5 to 8 per cent at 450 and 6 to 20 per cent at 500 mg/m2. A retrospective analysis of three randomised trials estimated 26 per cent at 550 mg/m2, against the 7 per cent at the same dose reported by the earlier large study. Those sources disagree, and the matrix prints both rather than choosing.

Hearing: in 1,422 cisplatin-treated testicular cancer survivors, measured hearing worsened with each additional 100 mg/m2 of cisplatin, and worsened faster in those with reduced kidney function.

Radiotherapy: QUANTEC gives the dose at which an organ at risk starts to fail, and those numbers decide the plan before the first fraction. Sparing one parotid gland to a mean dose below about 20 Gy, or both below about 25 Gy, is the difference between a dry mouth that partly recovers and one that does not. Spinal cord myelopathy risk stays under 1 per cent at 54 Gy. For the heart, Darby's cohort found no threshold at all: the rate of major coronary events rose 7.4 per cent per gray of mean heart dose.

Fertility: a cyclophosphamide equivalent dose below 4,000 mg/m2 left sperm production normal in 31 of 35 men in the St Jude Lifetime Cohort, and the ovarian dose at which ovarian failure is immediate falls with age, from 20.3 Gy at birth to 14.3 Gy at 30.

The practical use is narrow and real: ask what your cumulative dose was, or what dose the organ at risk is planned to receive, and read your own row rather than the headline figure.

## Fields

- Kind: Technology
- Status: established
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; evidence:strong; late-effects
- Principle: Late organ damage is usually a function of total exposure rather than of any single dose, because the injury accumulates in cells that do not divide and cannot be replaced: cardiomyocytes, cochlear hair cells, oocytes, salivary acinar cells. Where a threshold has been published it marks the point at which the proportion affected rises steeply, not a safe level below it, and for some effects, notably radiation coronary disease, no threshold has been found.
- Strengths: The number is in the notes and can be asked for; Thresholds change the plan before treatment rather than afterwards; They make dose capping, infusion schedule and organ sparing legible as the prevention they are
- Limitations: Thresholds exist for a minority of effects, and published sources sometimes disagree; They are population figures: individual susceptibility varies, including genetically; For radiation coronary disease no threshold has been found, so lower is simply better

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cumulative_dose
- Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials (Cancer 2003): https://doi.org/10.1002/cncr.11407
- Radiation dose-volume effects of the salivary glands, QUANTEC (Int J Radiat Oncol Biol Phys 2010): https://doi.org/10.1016/j.ijrobp.2009.06.090
- Risk of ischemic heart disease in women after radiotherapy for breast cancer (NEJM 2013): https://doi.org/10.1056/NEJMoa1209825
- Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer (Lancet Oncol 2014): https://doi.org/10.1016/S1470-2045(14)70408-5
- Predicting age of ovarian failure after radiation to a field that includes the ovaries (Int J Radiat Oncol Biol Phys 2005): https://doi.org/10.1016/j.ijrobp.2004.11.038

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Testicular germ cell tumours](https://onco.cc/cancers/testicular/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Hearing and tinnitus after platinum chemotherapy](https://onco.cc/technologies/hearing-after-platinum-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Oncofertility and fertility preservation](https://onco.cc/technologies/fertility-preservation/), [Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors](https://onco.cc/technologies/anthracycline-cardioprotection/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/)
- drugs: [Bleomycin](https://onco.cc/drugs/bleomycin/), [Carmustine](https://onco.cc/drugs/carmustine/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/)
- terms: [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-recovery-cumulative-dose.json